TLG Capital boosts Ugandan healthcare investment

Among the leaders, TLG Capital boosts Ugandan healthcare investment in a deal that reflects both a financial commitment and confidence in the country’s ability to deliver transformative outcomes through targeted capital allocation.

The London-based fund manager has completed a senior secured debt facility worth up to US$2m for an Ugandan healthcare distributor, strengthening the supply of critical pharmaceuticals across the market. For international observers, this transaction highlights the growing relevance of private credit in driving resilience in Africa’s health sector.

TLG Capital has earned its reputation as a strategic partner in Africa, focusing on sectors that combine commercial viability with development impact. Its presence in Uganda dates back to 2009, when it invested in Quality Chemicals Industries Limited, a manufacturer of essential antiretrovirals and antimalarials. That investment became a landmark transaction, enabling millions of patients to access affordable treatments.

Frederick Mutebi Kitaba, a promoter of the new deal, emphasised the trust built over more than a decade, underlining TLG’s role as a reliable partner. Such continuity is crucial in markets where healthcare systems are still developing yet demand for affordable medicine is surging.

The current transaction is TLG’s eighth investment in African healthcare, adding to its portfolio in Liberia, Nigeria, Benin, Togo, Niger, Burkina Faso, Mali and Côte d’Ivoire. By directing capital into essential services, the firm reinforces a strategy that balances profitability with tangible social progress.

Over the last fifteen years, Uganda has made substantial progress in human development. Child mortality has declined by two-thirds and AIDS-related deaths have fallen by 60%. These results are not coincidental but rather the outcome of deliberate public policies complemented by private investment in health.

According to TLG Capital CFO Isha Doshi, Uganda’s progress demonstrates the transformative potential of long-term capital. When financing is directed at healthcare with patience and vision, outcomes extend beyond profit and produce enduring improvements in national wellbeing.

For economists and foreign investors, Uganda offers a case study of how private credit can accelerate development gains while providing steady returns, especially in sectors where demand is resilient.

Across Africa, private credit is emerging as a crucial financial instrument. TLG has already completed 48 investments with 31 exits in 20 countries, underscoring its expertise. Private credit fills financing gaps where traditional banks face limitations, offering structured solutions tailored to small and medium-sized enterprises.

The newly launched Africa Growth Impact Fund II (AGIF II), backed by the IFC, Norfund, Swedfund and Bpifrance, extends this strategy. Its focus on SMEs ensures that capital reaches high-impact areas such as healthcare, where financing needs remain vast.

Private credit offers advantages beyond equity investment. Predictable cash flows, collateralisation, and contractual protections mitigate risk in frontier markets. In economies such as Uganda, these features are vital given the volatility and shallow capital markets.

Moreover, investing in healthcare offers a dual benefit: stable returns and measurable ESG outcomes. This alignment appeals to a growing pool of global capital that prioritises both profitability and impact.

Africa’s demographic expansion—its population is expected to double by 2050—creates unprecedented demand for healthcare. With limited public budgets, governments alone cannot bridge the gap. Private capital, particularly through credit structures, is already playing a transformative role.

The Ugandan example demonstrates that long-term capital deployment delivers both financial stability and improved social outcomes. For investors, it is an opportunity to enter a sector poised for growth while contributing to the continent’s human development.